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LIVER HISTOLOGY IN CO-INFECTION OF HEPATITIS C VIRUS (HCV) AND HEPATITIS G VIRUS (HGV)
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SUMMARY
As little is known about liver histology in the co-infection of hepatitis C virus (HCV) and hepatitis G virus (HGV), HGV RNA
was investigated in 46 blood donors with hepatitis C, 22 of them with liver biopsy: co-infection HCV / HGV (n = 6) and HCV isolated
infection (n = 16). Besides staging and grading of inflammation at portal, peri-portal and lobular areas (Brazilian Consensus), the
fibrosis progression index was also calculated. All patients had no symptoms or signs of liver disease and prevalence of HGV / HCV
co-infection was 15.2%. Most patients had mild liver disease and fibrosis progression index, calculated only in patients with known
duration of infection, was 0.110 for co-infection and 0.130 for isolated HCV infection, characterizing these patients as “slow fibrosers”.
No statistical differences could be found between the groups, although a lesser degree of inflammation was always present in co-
infection. In conclusion co-infection HCV / HGV does not induce a more aggressive liver disease, supporting the hypothesis that
HGV is not pathogenic.
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INTRODUCTION
Hepatitis C virus (HCV) and hepatitis G virus (HGV) are RNA
viruses of the flaviviridae family that can be transmitted by blood
transfusion and other parenteral and non-parenteral routes, with
persistence of viremia3,16. The high prevalence of HCV infection and its
morbidity is very well documented, as well as its relation to acute and
chronic hepatitis, cirrhosis and hepatocellular carcinoma2,25. As for HGV,
a virus more recently described, there are few evidences of morbidity
and many doubts about its etiologic role in liver diseases17,27.
The prevalence of HGV in blood donors is 1.5 to 1.7% in the United
States, but among them only 50% have elevated ALT3. Many studies
have detected the HGV-RNA in patients with chronic hepatitis and even
some cryptogenic cirrhosis19, but the initial reports of HGV having an
etiologic role in fulminant hepatitis were not confirmed in well conducted
studies13.
Co-infection by HCV and HGV has been studied in chronic hepatitis
submitted to Interferon treatment11, in serum and liver of deceased drug
users23, in association with cryoglobulinemia26, after bone marrow
transplantation22 and also in terminal liver disease, before and after hepatic
transplantation5. More recently, it was demonstrated that co-infection of
HGV in HIV patients reduces mortality29, due to inhibition of HIV
replication30. Histopathological variables, however, are seldom analyzed.
In one of these studies histological severity of the underlying chronic
hepatitis did not differ according to the HGV status, but hepatitis activity
was moderately increased in patients with associated HIV infection28.
Taking in consideration the recent classifications of chronic hepatitis
in which the stage of the disease is analyzed separately from
necroinflammatory activity, the grading of which is evaluated in portal,
peri-portal and lobular areas, it is worthwhile to investigate liver histology
in co-infection by HCV and HGV. As the prevalence of hepatitis G is
particularly high in Brazilian blood donors15, and hepatitis C infection
is usually mild in these asymptomatic patients, this is an interesting group
to investigate a possible synergism of both viruses in the production of
liver damage.
PATIENTS AND METHODS
The subjects were 46 blood donors investigated due to hepatitis C
positive tests. An epidemiological questionnaire was applied to detect
the possible source of infection as well as its duration in years. Liver
enzymes, namely ALT, GGT and other laboratorial tests were performed
initially and every 2 or 3 months in the follow up in order to decide
about liver biopsy and treatment. All the patients had no symptoms or
signs of liver disease and were anti-HCV positive by ELISA II test
confirmed by Immuno blotting test RIBA II. HGV-RNA was measured
by nested polymerase chain reaction using primers from the NS5 region
of the genome of HGV.
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Liver biopsy was indicated in patients with levels of ALT equal or
greater than 1.5 times the upper normal limit, at two consecutive
occasions, with more than 30 days interval. Biopsy specimens were
processed for routine histopathological examination, using four different
stains Haematoxilin-Eosin, Masson’s trichrome, Perls for iron and
impregnation of the reticulin framework by silver salts. Staging and
grading of all specimens were semiquantitative from 0 to 4, in accordance
with the criteria recently described by GAYOTTO et al.12 All this process
was blind, that means without knowledge of HGV status. Fibrosis
progression index (FPI) could be calculated only in those cases with a
very well determined duration of infection.
FPI or fibrosis progression rate per year, indirectly estimated, is the
ratio between the fibrosis stage in units (new classification of chronic
hepatitis) and the estimated duration of infection in years. In this model,
it is assumed that the patient has no fibrosis in the day of infection (F0)
and that fibrosis progression rate is constant20. For example, in a patient
with fibrosis stage 2 and 12 years duration of infection the fibrosis
progression index is 0.166 units of fibrosis per year.
In order to compare the groups HCV+HGV and HCV only, the scores
of the variables: staging, portal infiltrate, portal activity and lobular
activity were submitted to variance analyzes by Wilcoxon score test.
The values of p were obtained by the exact test of AGRESTI1. The
procedure NPAR1WAY of the SAS system was utilized for the analysis
of data.
RESULTS
HGV-RNA was detected in 7 of the 46 patients (15.2%). Liver biopsy
was performed in 22 patients, six of them with co-infection HGV and
HCV. Comparative demographic data of patients with co-infection or
hepatitis C only, submitted to histopathological examination, is depicted
in Table 1. Distribution of age and gender was the same between the
groups, as well as serum levels of ALT and GGT.
Blood transfusion was the most frequent source of infection, present
in one case with the HCV / HGV association and in 6 with HVC only.
Other possible sources of infection in the HCV / HGV group were drug
injections in one, tattooing in another and dentist manipulation in the
fourth. In two patients no source of infection was found. Duration of
infection was possible to be estimated in three patients of the HCV /
HGV group and in seven of the control group. It has varied from 10 to
15 years in the HVC / HGV group, with a mean FPI of 0.110 and from
8 to 25 years in the hepatitis C group with a mean FPI of 0.130.
No patients in both groups reached grade 4 either in staging or
inflammatory grading, as shown in Table 2. Most of the patients had
mild liver disease and comparing the sum of grades 0 and 1 with the
sum of grades 2 and 3, we have detected that inflammatory activity was
usually lower in peri-portal areas and higher in lobular areas. When
statistical analysis was applied the mean score values for inflammation
varied from 9.41 to 9.83 for HVC+HGV and from 12.12 to 12.28 for
HVC only. For staging (fibrosis) the mean score values were 11.25 for
HCV only and 12.16 for HCV+HGV (Table 3). Although no statistical
differences could be detected in terms of stage or activity between patients
with co-infection compared to isolated HCV infection, a low degree of
inflammation was constantly present in the HCV/HGV group.
DISCUSSION
The high prevalence of the association between HCV and HGV may
be due to the fact that HGV is transmitted through the same routes as
HCV, specially multiple blood transfusions, drug injection or other
parenteral routes9. Nevertheless the prevalence of 15.2% is in keeping
with that reported in literature, that has varied from 8.1%8, to 20%10 or
43%11, according to the epidemiology of the studied population. As we
Table 1
Comparative data between patients with co-infection HCV / HGV and
patients with HCV infection alone
Co-infection HCV infection “p”
HCV / HGV
Male (n) 4 13
Female (n) 2 3
Age (years) 36.5 ± 6.2 38.1 ± 9.4 0.6582
ALT (U/L) 74.5 ± 52.6 72.7 ± 46.3 0.9445
GGT (U/L) 51.5 ± 27.1 68.5 ± 51.4 0.3298
Table 2
Structural alterations and inflammatory activity in patients with co-infection HCV / HGV compared to HCV alone
0 1 2 3 4 (0+1) (2+3)
Staging Co-inf. 1 4 1 0 0 5 1
HCV only 6 6 2 2 0 12 4
Portal Co-inf. 0 4 2 0 0 4 2
Infiltrate HCV only 3 3 8 2 0 6 10
Peri-P. Co-inf. 1 5 0 0 0 6 0
activity HCV only 4 6 3 3 0 10 9
Lobular Co-inf. 0 4 1 1 0 4 2
activity HCV only 1 3 9 3 0 4 12
Co-inf. = Co-infection by HCV and HGV; Peri-P = Peri-Portal
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have studied blood donors with mild forms of chronic hepatitis C, our
prevalence is similar to the 10%, found in Brazilian healthy blood
donors15.
Our patients had no symptoms but due to high levels of ALT,
sometimes associated with elevated GGT, they were submitted to liver
biopsy in order to decide about the treatment for hepatitis C. Evaluation
of the histological variables is generally accepted as the main parameter
for treatment indication and patients with grades 0 or 1 in all these
parameters should not be submitted to the anti-viral treatment available
so far7.
The main parameter to evaluate progression of liver disease is the
development of fibrosis21. At histology, stage grade 2 means the presence
of fibrous septa out of the portal space, whereas in grades 0 and 1 fibrosis
is respectively absent and restricted to portal area. Considering this
variable, our co-infected patients behaved exactly the same as those
infected only by HCV.
Analyzing the fibrosis progression index, the more recent and
accepted way to evaluate the progression of hepatitis C21 we have found
similar results for co-infected and control groups. The index of 0.110
for co-infection and 0.130 for hepatitis C characterize our patients as
“slow fibrosers”. In fact, the mean values found in the group of 1157
pre-treatment cases of POYNARD et al. was 0.25220.
Analyzes of the necroinflammatory activity according to the METAVIR
classification has the advantage of combining the scores in the three areas
giving a single number to express this variable4. Nevertheless, as a
disadvantage, we lose the possibility of interpreting and correctly appreciate
the real value of inflammation in the three different areas. Using the
Brazilian consensus for the classification of chronic hepatitis we have
analyzed inflammation separately in portal, peri-portal (or interface) and
lobular or parenchymal areas12. Although scores 2 and 3 were more
frequently found in lobular than in peri-portal areas, in both groups of
patients the statistical analysis did not show significant differences. Mean
score values for HCV+HGV group were systematically lower than HCV
alone, but also without statistical significance.
Similarly to what is described by other authors10,11,28 we could not
detect a synergism between HCV and HGV and although not statistically
significant, the necro-inflammatory activity was, in this small group of
patients, a little lower in the co-infected patients. There are doubts about
the pathogenicity of HGV6,14,19,24 and even if HGV is really a hepatropic
virus with replication within liver cells. PESSOA et al.18 have shown
that levels of HGV RNA in liver and serum were similar in patients with
HGV infection alone compared with HGV/HCV co-infection. Differently
from HCV, the median liver/serum levels of HGV RNA were less than
unity, what is consistent with serum contamination of liver tissue, leading
to the conclusion that liver is not the main site of HGV replication.
Although there are no clues for a protective function of HGV in
hepatitis C, since it does not affect HCV replication, the recent findings
of mortality reduction in patients co-infected with HIV + HGV, compared
with those with HIV alone29,30, claims for a better evaluation of hepatic
histology in patients co-infected with HGV. Our results, showing that
co-infection does not induce a more aggressive liver disease, supports
the hypothesis of no pathogenicity of HGV.
RESUMO
Histologia hepática na co-infecção do vírus da hepatite C (VHC) e
vírus da hepatite G (VHG)
As escassas informações sobre histologia hepática na co-infecção
do vírus da Hepatite C (VHC) e vírus da Hepatite G (VHG) nos levou a
investigar o RNA-VHG em 46 doadores de sangue com hepatite C, dos
quais 22 com biópsia hepática: co-infecção VHC / VHG (n = 6) e infecção
isolada do VHC (n = 16). Além de estadiamento e gradação da atividade
inflamatória nas áreas portal, peri-portal e lobular, segundo o Consenso
Brasileiro, calculamos também o índice de progressão da fibrose. Os
pacientes estudados não apresentavam sintomas ou sinais físicos de
doença hepática. A prevalência da co-infecção VHC / VHG foi de 15,2%.
A maior parte dos pacientes apresentava-se com lesão hepática discreta
e o índice de progressão da fibrose, calculado apenas nos pacientes com
duração conhecida da infecção, foi de 0,110 para os co-infectados e de
0,130 para aqueles com infecção isolada pelo VHC, caracterizando esses
pacientes como “fibrosantes lentos”. Não foram encontradas diferenças
estatísticas entre os grupos, apesar de menor grau de inflamação em
todas as áreas analisadas, nos casos de co-infecção. Em conclusão, a co-
infecção VHC / VHG não induz o surgimento de lesão hepática mais
grave, favorecendo a hipótese de que o VHG não é patogênico.
Table 3
Results of the 4 histological variables, according to Wilcoxon variance analysis
Variable Groups Sum of scores Standard Deviation Mean  score p
Staging HCV + HGV 73.0 12.66 12.16 0.8628
HCV only 180.0 12.66 11.25
Portal infiltrate HCV +HGV 59.0 12.66 9.83 0.4415
HCV only  194.0 12.66 12.12
Peri-portal activity HCV+HGV 58.0 12.57 9.66 0.4291
HCV only  195.0 12.57 12.18
Lobular activity HCV+HGV 56.5 12.71 9.41 0.3503
HCV only 196.5 12.71 12.28
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